Chest pain

Public Advisory - Fake Viagra seized from Jug City store in Scarborough, ON

Retrieved on: 
Venerdì, Aprile 26, 2024
Sale, Pharmacy, Stroke, Safety, Risk, Hearing loss, Nitroglycerin, Natural product, Health, Dizziness, Health Canada, Plasma protein binding, Blister, Counterfeit, Policy, NPN, Prescription drug, Headache, Counterfeit medications, Chest pain, DIN, Dietary supplement

Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).

Key Points: 
  • Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).
  • This is in addition to several other unauthorised sexual enhancement products seized from the same store.
  • For more information regarding Health Canada's approach to counterfeit health products, please consult Health Canada's Policy on Counterfeit Health Products .
  • Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM).

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Retrieved on: 
Giovedì, Aprile 18, 2024
RVV, FDA, Brain, COVID, SARS-CoV-2, Blood, Infection, Research, Therapy, Classification, Treatment, Fatigue, Revive, Arrhythmia, Diagnosis, Lawson Health Research Institute, Biomarker, Chest pain, COVID-19

The meeting date assigned by the FDA is June 7, 2024.

Key Points: 
  • The meeting date assigned by the FDA is June 7, 2024.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the Product as a potential blood biomarker diagnostic that characterizes long COVID.
  • Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
  • The Company entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to the intellectual property of novel blood biomarkers that characterize long COVID.

Biome Launches Innovative Acute Coronary Syndrome (ACS) Module to Enhance Care Delivery

Retrieved on: 
Martedì, Aprile 16, 2024
Software, Managed Care, General Health, Professional Services, Data Management, Technology, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Cardiology, Health, Biome, Emergency department, ACS, Health care, Accreditation, Chest pain, Patient, Length of stay, Hospital, Nursing

Healthcare systems face the ongoing challenge of managing bed capacity while striving to provide high-quality patient care and achieve excellent clinical outcomes.

Key Points: 
  • Healthcare systems face the ongoing challenge of managing bed capacity while striving to provide high-quality patient care and achieve excellent clinical outcomes.
  • Biome's new ACS module is designed to assist healthcare systems in managing the complexities associated with chest pain care.
  • As hospitals increasingly pursue accreditation for chest pain center certification, having immediate access to performance data is critical.
  • These advanced insights equip leaders with the insights they need to maximize operational capacity and enhance patient outcomes, ultimately leading to improved healthcare experience for patients.

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

Retrieved on: 
Giovedì, Aprile 11, 2024
Technology, Biotechnology, Health, Biometrics, Apps, Applications, Other Health, Telemedicine, Virtual Medicine, Medical Devices, Software, Managed Care, Hospitals, Health Technology, Clinical Trials, Cardiology, American College, Telehealth, ACC, Periodic breathing, Dizziness, ECG, Imperial College London, Patient, Multimedia, Chest pain, SHL, Photograph, ED, Medical imaging

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.
  • The TELE-ACS clinical trial, conducted at a large tertiary center in London, UK, from January 2022 to April 2023, involved 337 participants.
  • Moreover, the study was also published in the leading Journal of the American College of Cardiology (JACC).
  • These groundbreaking clinical results are an endorsement that propels us forward in our mission to redefine patient care, demonstrating the tangible benefits and efficiency of our telemedicine solutions on a global scale."

Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients

Retrieved on: 
Giovedì, Aprile 25, 2024
Education, Patient, Stenosis, Social media, Dizziness, Aortic stenosis, Artificial intelligence, Cardiology, MetroHealth, SAVR, Senior, TAVR, Fatigue, Physician, Surgery, Aortic valve, Chest pain, Cardiovascular disease, Heart, Medical device

LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.

Key Points: 
  • LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.
  • Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly.
  • Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
  • Because treatment continues to increase and evolve, the "Aortic Stenosis Patient Activation Platform", developed by Heart-Valve-Surgery.com with support from Medtronic and a world-renowned team of physicians, will increase awareness and education for aortic stenosis patients.

Global Pulmonary Hypertension Community 'United for' World PH Day 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024
Social media, Pulmonary hypertension, Policy, Person-centered therapy, Disease, Oxygen, Patient, PHA, Legislation, Fatigue, Access, Caregiver, Medicare, SOAR, Pulmonary Hypertension Association, Diagnosis, Chest pain, Organization

WASHINGTON, April 24, 2024 /PRNewswire-PRWeb/ -- The Pulmonary Hypertension Association will unite with over 80 organizations globally on Sunday, May 5, to recognize World Pulmonary Hypertension Day. World PH Day aims to raise awareness of pulmonary hypertension, a rare, complex, life-threatening disease that affects more than 75 million adults and children worldwide across all ethnic groups. There is currently no cure for PH, or high blood pressure in the lungs that causes symptoms such as shortness of breath, fatigue and chest pain.

Key Points: 
  • World pulmonary hypertension community to unite on May 5 to raise awareness, offer support and advocate for PH.
  • WASHINGTON, April 24, 2024 /PRNewswire-PRWeb/ -- The Pulmonary Hypertension Association will unite with over 80 organizations globally on Sunday, May 5, to recognize World Pulmonary Hypertension Day.
  • World PH Day aims to raise awareness of pulmonary hypertension, a rare, complex, life-threatening disease that affects more than 75 million adults and children worldwide across all ethnic groups.
  • PHA encourages the global PH community to raise awareness about key issues facing those with PH using resources from its World PH Day webpage .

Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers

Retrieved on: 
Martedì, Aprile 23, 2024
University, Cancer, NHS, Risk, Coronary artery disease, CDC, Heart, VCL, MD, Mace, Partnership, Research, MRCP, Atherosclerosis, Patient, Splenic infarction, Death, Chest pain, Artery, Plaque, Imaging, CCTA

OXFORD, England and SURREY, England , April 23, 2024 /PRNewswire/ -- Surrey Cardiovascular Clinic (SCVC), Southern England's leading centre of excellence for the prevention and treatment of cardiovascular and cancer issues, has partnered with Imaging provider VCL SURREY and Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • SCVC will provide the CaRi-Heart AI-based cardiac assessment as a central part of the organisations 's employee wellness initiative for UK employers.
  • In combination with the programme's other tests, Cari-Heart provides the ability to predict future heart attacks and atherosclerosis many years before symptoms occur.
  • We are pleased to announce our partnership with Surrey Cardiovascular Clinic and their imaging partner VCL Surrey to enhance accessibility to CaRi-Heart technology for employees throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.
  • The CaRi-Heart technology is currently in clinical use in various NHS and private hospitals in the UK, as well as within the EU and Australia.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Martedì, Marzo 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System's Cost-Effectiveness

Retrieved on: 
Lunedì, Aprile 8, 2024
Faculty, Chest pain, Coronary artery disease, Massachusetts General Hospital, Health, Incidence, Risk, Patient, Anxiety, MD, Master of Science, Emergency department, American College, ED, Physician, ACC, CAD, Medical device

"This not only leads to increased healthcare costs but also results in the improper utilization of resources.

Key Points: 
  • "This not only leads to increased healthcare costs but also results in the improper utilization of resources.
  • Additionally, the incidence of missed cardiac events with the CADScor System was remarkably low, indicating that the anticipated economic benefit did not compromise clinical outcomes.
  • "This study reaffirms the comprehensive value proposition of the CADScor System for patients, physicians, and payors alike.
  • Physicians can easily and quickly determine the next steps, facilitating cost efficiencies for healthcare systems and payors by reducing unnecessary testing."

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Lunedì, Aprile 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.